Peregrine Capital Management LLC Increases Stake in Vaxcyte in Q1

Summary

Peregrine Capital Management LLC acquired 86,244 shares of Vaxcyte, Inc. (NASDAQ: PCVX) in the first quarter, valued at approximately $3.26 million, representing about 0.07% of the holding. Other institutional investors have also increased their investment in Vaxcyte. Analysts have mixed ratings on the stock, with a common target price of $136.50. Vaxcyte’s stock opened at $32.94, with a 12-month price range of $27.66 to $121.06. The company focuses on developing novel protein vaccines against bacterial infectious diseases.Market Beat

Impact Analysis

First-Order Effects: Peregrine Capital Management’s investment signifies confidence in Vaxcyte’s business prospects, particularly its focus on novel protein vaccines against bacterial infections. This may enhance Vaxcyte’s financial stability and boost investor sentiment, potentially driving stock price appreciation towards the target price of $136.50. However, analysts have mixed ratings, which indicates varying opinions on the company’s growth potential and market risks.Market Beat
Second-Order Effects: As institutional investors like Quest Partners LLC and Meeder Asset Management Inc. also increase their holdings in Vaxcyte, it suggests growing interest in the vaccine sector, potentially leading to increased competition and innovation in the industry.Market Beat
Investment Opportunities: Investors might consider options strategies to capitalize on expected price movements, such as call options if they anticipate appreciation or protective puts to mitigate downside risks given the mixed analyst ratings.Market Beat